Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers

  • GianMaria Miolo1, 2Email author,
  • Vincenzo Canzonieri3,
  • Clelia De Giacomi2,
  • Lara Della Puppa1,
  • Riccardo Dolcetti4,
  • Davide Lombardi2,
  • Tiziana Perin3,
  • Simona Scalone2,
  • Andrea Veronesi2 and
  • Alessandra Viel1
BMC Cancer20099:360

DOI: 10.1186/1471-2407-9-360

Received: 29 June 2009

Accepted: 10 October 2009

Published: 10 October 2009

Abstract

Background

BRCA1 gene-related tumours are more frequently estrogen receptor (ER) and progesterone receptor (PR) negative with a lower prevalence of human epidermal growth factor receptor 2 (HER2) overexpression or amplification. We evaluated the effectiveness of a combination of homogeneously selected criteria and immunohistochemical (IHC) characteristics of Familial Breast Cancers (FBCs) in detecting BRCA1 mutation carriers.

Methods

Primary breast tumours from 93 FBC patients defined by specific eligibility criteria, based on personal and familial tumour history, were evaluated by Allred's method. The BRCA1 molecular analysis, including Multiplex Ligation-dependent Probe Amplification (MLPA), was considered as the gold standard assay.

Results

A total of 10 BRCA1 pathogenetic mutations was found. With the exclusion of the tumours characterized by double positive receptorial status and/or strong HER2 positivity (3+), we identified 22 patients, 10 of whom resulted as BRCA1 mutation carriers. The sensitivity, specificity, positive and negative predictive values were 100%, 83.3%, 45.4% and 100% respectively.

Conclusion

Our findings suggest that the IHC analysis by Allred's method improves our ability to select patients for BRCA1 testing.

Background

One of the still unexplained features of BRCA1-mutant breast tumours is their frequent lack of ER expression; in fact, up to 90% of these tumours exhibit a loss of ER expression [1, 2]. In addition, BRCA1-associated breast cancers frequently show a low prevalence of HER2 overexpression or amplification [35].

Patients with a strong family history of breast and/or ovarian cancer are counselled to receive genetic testing for mutations in the BRCA1/BRCA2 genes. The selection of patients is crucial and relies mostly on family history and phenotype ascertainment [68]. In general, only 20-40% of screened families, even using rigid selection criteria, have positive mutation results [9, 10]. In particular, the rate of mutations in Italian breast and/or ovarian cancer families is rather controversial and ranges from 8% to 37% [11]. Moreover, it has been recently pointed out that only less than 10% of cases with a positive family history harbour a BRCA1 mutation [12].

In this study, we evaluated the effectiveness of a combination of selected eligibility criteria and IHC characteristics of breast cancer to identify patients who have a higher probability of being BRCA1 mutation carriers.

Methods

From September 2002 to October 2008, a total of 93 female index cases affected with breast cancer complying with the eligibility criteria for BRCA testing in use at the Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy were enrolled in the study [13]. Cases affected with ovarian cancer and male breast cancer were excluded. Written informed consent for genetic testing was obtained from all the participants. The study fully conformed to the Declaration of Helsinki and to the current Italian Legislation and was also approved by the Ethical Committee of the Institute.

Genomic DNA was purified from blood samples obtained from each proband. Screening for mutations in the BRCA1/BRCA2 genes was carried out by Denaturing High Performance Liquid Cromatography and direct sequencing techniques. Primer sequences and PCR conditions have been previously described [1416]. Germline rearrangements of BRCA1/BRCA2 genes were also analysed by Multiple Ligation-dependent Probe Amplification (MLPA). Missense, silent, and intronic mutations, whose clinical significance have not yet been reported, were classified as genetic variants of uncertain significance (unclassified variant, uv) in accordance with the BIC database [17].

Ventana Medical Systems clone 6F11 (Ventana Medical Systems, Inc., Tucson, AZ) for the evaluation of the ER and Ventana Medical Systems clone 1E2 for the evaluation of the PR were used. With the Allred score, the proportion score (PS) and the intensity score (IS) are assessed in six and four grades, respectively 0-5 and 0-3, then the total score is assessed in eight grades (0 and 2-8) [18]. Tumours with an IHC total score of 3 or more were reported as positive. The IHC analysis of HER2 was performed by staining with the rabbit anti-human HER2 antibody clone 4B5 (Ventana Medical Systems). A score index of 0, 1, 2 and 3 was used, corresponding respectively to negative, weak, moderate and strong staining intensity, and the percentage of positive cells at each intensity was estimated subjectively.

The sensitivity, specificity, and positive and negative predictive values were calculated from the results of the IHC analysis to predict for BRCA1 mutations.

Results

In total, 19 different BRCA1/BRCA2 deleterious mutations were identified in the 93 unrelated patients. Ten (10.8%) patients resulted BRCA1 mutation carriers whereas in nine (9.7%) a BRCA2 mutation was found (Tables 1 and 2). The prevalence of BRCA1 large genomic rearrangements accounted for 20% (2/10) of the BRCA1 gene mutation spectrum. No large deletions or duplications involving the BRCA2 gene were observed. In this series, all BRCA1 tumours showed a double or a single negative hormonal receptorial status, whereas HER2 was invariably negative or only weakly expressed (Table 1).
Table 1

BRCA1 group and IHC tumour characteristics.

ID pts

Age at diagnosis

DNA

Mutation effect

Grade

° ER (score)

° PR (score)

§HER2

^ BRCAPRO BRCA1

^ BRCAPRO BRCA2

^ BRCAPRO total

*BC and CBC cases

*OC cases

BR332

42

633delC

233X

3

- (2)

- (0)

-

0.975

0.013

0.987

1 (27)

2 (35, 56)

BR334

26

2428C>A

S770X

3

- (0)

- (0)

-

0.658

0.091

0.748

1 (53)

1 (75)

BR341

45

del 9-19

del ex. 9-19 ter 184

3

- (0)

- (0)

-

0.320

0.524

0.841

3 (37, 48 M, 52)

/

BR352

37

del 23-24

unpredictable

3

- (0)

- (0)

1+

0.777

0.075

0.850

1 (29+42 CBC)

/

BR384

50+56 CBC

795delT

233X

3

- (0)

- (0)

1+/2+

0.529

0.085

0.613

2 (56, 57)

1 (57)

BR386

40

1806C>T

Q563X

3

- (0)

- (0)

1+/2+

0.311

0.048

0.358

/

1 (69)

BR392

31

795delT

233X

3

- (0)

- (0)

-

0.813

0.066

0.876

1 (46+48 CBC)

/

BR441

46

5181delGTT

1688delV

3

- (0)

- (0)

-

0.166

0.036

0.202

3 (46, 47, 48)

1 (63)

BR507

22

633delC

233X

3

- (0)

- (0)

1+

0.091

0.015

0.106

/

/

BR587

38+60 CBC

300T>G

C61G

3

- (0)

- (0)

1+

0.922

0.063

0.984

2 (40, 43)

1 (60)

BC = breast cancer; CBC = controlateral breast cancer; OC = ovarian cancer; / = no cases; M = male. The ages at diagnosis of the first cousins are in boldface type; ° IHC Allred total scores of 3 or more were reported as positive. §HER2 IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO software http://www.isds.duke.edu/~gp/brcapro.html; * number of additional tumours in the family and ages of onset in parentheses.

Table 2

BRCA2 group and IHC tumour characteristics.

ID pts

Age at diagnosis

DNA

Mutation effect

Grade

° ER (score)

° PR (score)

§HER2

^ BRCAPRO BRCA1

^ BRCAPRO BRCA2

^ BRCAPRO total

*BC, CBC and BBC cases

*OC cases

BR288

36

9326insA

3043X

3

+ (6)

+ (5)

1+

0.003

0.026

0.029

/

1 (44)

BR295

54

657insC

157X

2

+ (8)

+ (5)

-

0.029

0.405

0.434

2 (41+43 CBC, 48)

/

BR312

47

IVS16-2A>G

Exon skipping

3

+ (5)

+ (3)

1+

0.002

0.365

0.367

2 (47, 77 M)

/

BR342

44+52 CBC

9106C>T

Q2960X

3

+ (8)

+ (3)

2+

0.006

0.182

0.187

2 (59, 68+75 CBC)

/

BR360

43

IVS23+1G>T

Exon skipping

3

+ (4)

+ (6)

2+/3+

0.088

0.553

0.640

1 (30 BBC)

/

BR382

44+63 CBC

7507del7

2168X

3

+ (6)

+ (8)

1+

0.002

0.061

0.063

1 (35)

/

BR410

24

9325delA

3061X

2

+ (7)

+ (4)

1+

0.170

0.557

0.727

1 (47)

2 (54, 73)

BR450

48

4450C>T

Q1408X

1

+ (7)

+ (7)

-

0.010

0.044

0.054

2 (52, 55)

2 (38, 55)

BR571

31

3036del4

959X

2

+ (3)

+ (6)

3+

0.001

0.037

0.038

3 (50, 50, 61)

/

BC = breast cancer; CBC = controlateral breast cancer; BBC = bilateral breast cancer; OC = ovarian cancer; / = no cases; M = male. ° IHC Allred total scores of 3 or more were reported as positive. §HER2 IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO Software http://www.isds.duke.edu/~gp/brcapro.html; * number of additional tumours in the family and ages of onset in parentheses.

Altogether, 21 cases showed an uv alteration of BRCA1 and/or BRCA2 genes: 7 BRCA1 uv, 7 BRCA2 uv, 5 cases with a variant in both genes, 1 triple BRCA1 uv and 1 double BRCA2 uv associated with a BRCA1 uv, respectively (Table 3).
Table 3

BRCA1 and/or BRCA2 uv group and IHC tumour characteristics.

 

ID pts

Age at diagnosis

DNA

Mutation effect

Grade

° ER (score)

° PR (score)

§HER2

^ BRCAPRO BRCA1

^ BRCAPRO BRCA2

^ BRCAPRO total

BC, CBC and BBC cases

OC cases

BRCA1 uv

             
 

BR417

30

1186A>G

Q356R

2

+ (3)

- (0)

3+

0.015

0.040

0.055

1 (46)

/

 

BR427

48

4274A>G

L1385L

2

+ (7)

+ (7)

1+

0.000

0.010

0.011

1 (44)

/

 

BR437

50

2351T>G

A744A

1

+ (5)

+ (3)

1+

0.000

0.014

0.015

3 (50, 55, 59)

/

 

BR523

48 BBC

IVS20+60ins12

 

2

+ (6)

+ (7)

1+

0.018

0.245

0.263

3 (50,50, 52)

/

 

BR570

47

5221T>C

L1701P

3

- (0)

+ (3)

3+

0.094

0.169

0.264

2 (49+52 CBC, 56)

/

 

BR647

49

1186A>G

Q356R

3

+ (8)

+ (7)

1+

0.005

0.010

0.015

3 (65, 67, 70)

/

 

BR658

43

1186A>G

Q356R

3

+ (6)

+ (6)

2+

0.001

0.069

0.070

3 (50+63 CBC, 57, 60*)

/

 

BR665

65 BBC

655A>G

Y179C

2

+ (5)

+ (5)

-

0.001

0.004

0.004

3 (60, 80, 80)

/

   

1575T>C

F486L

         
   

1767A>G

N550H

         

BRCA2 uv

             
 

BR376

55

IVS2-7T>A

 

2

+ (6)

+ (3)

1+

0.000

0.008

0.008

2 (45, 90)

/

 

BR390

51 OC+54 BBC

6328C>T

R2034C

2

+ (5)

+ (8)

-

0.130

0.648

0.777

3 (34, 39, 40)

/

 

BR458

44+49 CBC

5972T>C

T1952I

2

+ (7)

+ (5)

-

0.025

0.433

0.459

2 (50 BBC, 70)

/

 

BR486

56

2457T>C/ 9329A>G

H743H/R3034Q

3

+ (5)

+ (8)

-

0.000

0.000

0.000

4 (57, 71, 75, 90)

/

 

BR505

67

6751C>G

Q2175E

1

+ (7)

+ (7)

-

0.018

0.426

0.444

4 (40 BBC, 50 BBC, 53 BBC, 58)

/

 

BR538

62

4236G>A

L1356L

2

+ (7)

+ (7)

-

0.001

0.025

0.026

2 (50 BBC, 56)

/

 

BR587

38+60 CBC

IVS24-113T>G

 

3

- (0)

- (0)

1+

0.922

0.063

0.984

2 (40, 43)

1 (60)

BRCA1/2 uv

             
 

BR514

57

3238G>A

S1040N

1

+ (7)

+ (8)

-

0.001

0.061

0.062

4 (42, 45, 49, 55)

/

   

IVS4+67A>C

1613A>G

E462G

         
 

BR552

70

4158A>G

R1347G

3

+ (5)

+ (3)

3+

0.000

0.012

0.012

3 (40, 47, 65)

/

   

6328C>T

R2034C

         
 

BR567

50

IVS4+67A>C

 

3

+ (6)

+ (7)

-

0.009

0.215

0.225

3 (37 BBC, 50 BBC, 50)

1 (59)

   

2457T>C

H743H

         
 

BR571

31

IVS9-34T>C

 

2

+ (3)

+ (6)

3+

0.001

0.037

0.038

3 (50, 50, 61)

/

   

5972C>T

T1951M

         
 

BR580

43

3238G>A

S1040N

3

+ (7)

+ (5)

1+

0.001

0.030

0.031

2 (46, 68)

/

   

1409A>G

E394A

         
 

BR640

30

855T>G

L246V

3

+ (7)

- (0)

1+

0.117

0.261

0.378

2 (30, 40)

/

   

4296G>A

L1356L

         

BC = breast cancer; CBC = controlateral breast cancer; BBC = bilateral breast cancer; OC = ovarian cancer; / = no cases; M = male. The ages at diagnosis of the first cousins are in boldface type; ° IHC Allred total scores of 3 or more were reported as positive. §HER2 IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO software http://www.isds.duke.edu/~gp/brcapro.html; * number of additional tumours in the family and ages of onset in parentheses.

To evaluate the sensitivity and specificity of the IHC screening in a selected set of patients, the combination between BRCA1 point mutation screening and MLPA was considered as the gold standard assay. According to the receptorial status, patients were divided into two groups. The first group included all the ER negative and/or PR negative tumours, whereas the second group consisted of the double positive ones. The BRCA1/2 negative mutation group is shown in Table 4.
Table 4

non BRCA1/2 mutation group and IHC tumour characteristics.

ID pts

Age at diagnosis

Grade

° ER (score)

° PR (score)

§HER2

^ BRCAPRO BRCA1

^ BRCAPRO BRCA2

^ BRCAPRO total

*BC, CBC and BBC cases

*OC cases

BR271

40

G2

+ (7)

+ (5)

1+/2+

0.002

0.036

0.038

1 (37)

/

BR275

28 BBC

G3

+ (7)

+ (7)

-

0.067

0.578

0.645

1 (55)

/

BR281

42

G3

+ (6)

+ (4)

3+

0.008

0.222

0.230

6 (27, 36, 50, 60, 50 BBC, 60)

/

BR297

54

G3

- (0)

- (0)

-

0.064

0.018

0.081

2 (42, 69)

/

BR304

41

G3

+ (7)

+ (6)

-

0.002

0.058

0.060

2 (52, 64)

/

BR315

46 BBC

G2

+ (7)

+ (7)

1+

0.012

0.160

0.172

1 (49)

/

BR335

64

G2

+ (8)

- (0)

1+

0.002

0.017

0.020

2 (57, 70)

1 (69)

BR338

36

G3

- (0)

- (0)

3+

0.131

0.029

0.160

2 (45, 71)

/

BR339

74

G2

+ (7)

+ (7)

-

0.003

0.085

0.088

3 (39, 61+63 CBC, 66)

2 (54, 64)

BR340

35

G3

+ (7)

- (0)

3+

0.009

0.026

0.035

2 (43, 59)

/

BR348

55

G3

+ (7)

- (0)

1+

0.009

0.062

0.071

2 (56, 56)

1 (68)

BR350

42

G3

+ (7)

+ (7)

2+

0.001

0.014

0.015

4 (49, 57, 61*, 70*)

/

BR357

35

G3

+ (6)

- (0)

-

0.002

0.014

0.016

2 (55, 67)

/

BR377

46

G3

+ (7)

+ (6)

-

0.000

0.007

0.007

2 (46, 70)

/

BR380

30

G2

- (0)

- (0)

1+/2+

0.303

0.067

0.370

3 (42, 64, 64)

/

BR381

45

G3

+ (5)

+ (6)

-

0.000

0.004

0.004

2 (45, 85)

/

BR398

50

G2

+ (5)

+ (3)

-

0.000

0.020

0.020

5 (60, 61, 65, 70, 98)

/

BR403

53+57 CBC

G3

+ (7)

+ (7)

-

0.000

0.006

0.007

1 (82+84 CBC)

/

BR408

53

G2

+ (6)

+ (4)

-

0.000

0.002

0.002

3 (71*, 85*, 67°)

/

BR414

60

G2

- (2)

+ (4)

-

0.003

0.101

0.104

2 (73M, 50)

/

BR418

27

G3

- (0)

- (0)

3+

0.093

0.015

0.108

/

/

BR422

55

G3

+ (6)

- (2)

-

0.002

0.014

0.016

2 (50, 53)

/

BR424

45

G2

+ (5)

+ (7)

2+

0.006

0.113

0.119

1 (49+59 CBC)

/

BR425

27

G2

+ (3)

+ (5)

3+

0.001

0.012

0.013

/

/

BR439

52

G3

- (0)

- (2)

-

0.052

0.030

0.082

3 (36, 60, 70)

1 (78)

BR445

54

G1

+ (6)

+ (3)

1+

0.004

0.067

0.072

2 (45, 48+52 CBC)

/

BR446

50

G2

+ (7)

+ (4)

1+

0.000

0.008

0.008

1 (40)

/

BR447

65

G2

+ (8)

+ (6)

-

0.001

0.045

0.046

2 (58, 79)

/

BR449

50

G2

+ (6)

+ (7)

-

0.001

0.020

0.021

1 (37)

/

BR457

53

G3

+ (4)

- (2)

3+

0.000

0.003

0.004

2 (55, 55)

/

BR463

48

G3

+ (6)

+ (5)

-

0.001

0.032

0.033

1 (67 BBC)

/

BR480

53

G2

+ (7)

+ (7)

-

0.004

0.135

0.139

3 (31, 50, 53)

/

BR484

57

G2

+ (7)

+ (7)

1+

0.000

0.014

0.014

2 (55, 73+78 CBC)

/

BR494

58

G3

+ (5)

- (0)

-

0.020

0.352

0.372

4 (40, 43, 45, NA M)

/

BR498

46

G2

+ (5)

+ (7)

-

0.005

0.837

0.841

4 (42 BBC, 48, 49M, 74)

/

BR506

55

G1

- (0)

+ (5)

-

0.000

0.012

0.012

3 (62, 30, 76)

/

BR535

56

G3

+ (7)

+ (7)

1+

0.000

0.019

0.019

3 (47, 53, NA)

/

BR542

45

G3

+ (7)

+ (7)

1+

0.007

0.112

0.119

2 (36,62)

/

BR545

63

G2

+ (7)

+ (6)

1+

0.000

0.003

0.003

2 (64, 70)

/

BR549

36

G3

+ (6)

+ (5)

1+

0.013

0.142

0.155

1 (36)

/

BR553

54

G2

+ (7)

+ (6)

1+

0.011

0.486

0.497

2 (49, 65)

1 (55)

BR558

45

G1

+(7)

+ (8)

1+

0.000

0.029

0.030

3 (48, 78, 78)

/

BR560

78

G2

+ (7)

+ (3)

1+

0.000

0.025

0.025

3 (45, 48, 78)

/

BR569

41

G2

+ (7)

+ (8)

-

0.114

0.072

0.185

/

2 (60, 60)

BR582

27

G3

+ (6)

+ (8)

-

0.001

0.016

0.016

/

/

BR584

42

/

+ (5)

+ (6)

1+

0.001

0.017

0.018

3 (40, 54, 69)

/

BR592

67

G2

+(7)

+(7)

2+

0.001

0.035

0.036

4 (48, 52, 55, 60)

/

BR593

48

G3

+(7)

+ (3)

1+

0.088

0.242

0.330

3 (33 BBC, 65, 70)

1 (24)

BR599

39+44 CBC

G3

+ (6)

- (0)

3+

0.187

0.370

0.557

2 (44, 60)

/

BR603

40

G2

+ (7)

+ (7)

-

0.001

0.032

0.033

1 (36)

/

BR615

49

G1

+ (7)

+ (7)

1+

0.000

0.004

0.004

2 (49, 50)

/

BR649

80

G2

+ (7)

+ (6)

1+

0.001

0.404

0.406

2 (31, 44 BBC)

/

BR650

47

G3

+ (6)

- (0)

-

0.004

0.017

0.021

1 (45)

/

BR656

43

G2

+ (6)

+ (7)

1+

0.003

0.269

0.272

3 (40, 44, 52)

/

BR666

56

G2

+ (8)

+ (6)

1+

0.132

0.201

0.332

3 (39, 50, 51)

3 (49, 54, 61)

BC = breast cancer; CBC = controlateral breast cancer; OC = ovarian cancer; / = no cases; M = male. The ages at diagnosis of the first cousins are in boldface type; ° IHC Allred total scores of 3 or more were reported as positive. §HER2 IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO software http://www.isds.duke.edu/~gp/brcapro.html; * number of additional tumours in the family and ages of onset in parentheses.

Twenty-nine tumours did not show a positive staining for ER and/or PR hormone receptors. Notably, 10 of these negative cases were from BRCA1 mutation carriers (Table 5). Furthermore, not considering the cases showing a strong HER2 positivity (3+), the mutation screening could have been performed in only 22 patients, detecting the same number of BRCA1 mutations (Table 6).
Table 5

Relation between breast cancer receptorial status and BRCA1 mutant genotype.

Receptorial status

BRCA1 carriers

non-BRCA1 cases

Total

° ER- and/or PR-

10

19

29

ER+/PR+

-

64

64

Total

10

83

93

Sensitivity 100%; Specificity 77.1%; Predictive Positive Value 34.4%; Predictive Negative Value 100%; ° IHC Allred total scores of 3 or more were reported as positive.

Table 6

Relation between breast cancer receptorial status and BRCA1 mutant genotype excluding HER2 3+ cases.

Receptorial status

BRCA1 carriers

non-BRCA1 cases

Total

° ER- and/or PR-

10

12

22

ER+/PR+

-

60

60

Total

10

72

82

Sensitivity 100%; Specificity 83.3%; Predictive Positive Value 45.4%; Predictive Negative Value 100%; ° IHC Allred total scores of 3 or more were reported as positive.

The detection rate of BRCA1 mutations was shown to increase from 10.8% (10/93) to 45.5% (10/22), thus allowing the minimization of the number of patients who should undergo BRCA1 mutation screening.

Discussion

BRCA1-associated tumours have a high probability of being ER negative (up to 90%), PR negative (79%) and with a low frequency of HER2 expression [4, 5, 1921]. Physical co-deletion of BRCA1 and HER2 loci on chromosome 17q, occurring as a second somatic inactivating hit, may be at least partly responsible for the low incidence of HER2 expression oramplification in BRCA1-associated carcinomas [2224].

In the present series, four of the five triple negative tumours (80%) harboured BRCA1 mutations. Consistently with these data, the screening carried out by Musolino et al detected 10 BRCA1 mutations: seven of the eight IHC evaluated BRCA1-related tumours had a triple negative phenotype (87%) and all were negative for HER2 expression [25].

We report an overall prevalence of BRCA1 mutations of 10.8% (10/93). The FBC screening procedure based on the selection of women who were ER and/or PR negative and with weakly expressed HER2, showed a sensitivity in BRCA1 mutation carriers of 100% and a specificity of 83.3%, with a positive predictive value of 45.4% and a negative predictive value of 100%. Moreover, all BRCA1 mutation carriers were identified by using IHC screening, thus confirming that the Allred's method can be used to accurately predict the probability of being a carrier of the BRCA1 mutation.

The IHC test has a very high sensitivity and specificity, and may substantially improve the detection of BRCA1 pathogenetic mutations in families with hereditary breast cancer.

It has been suggested that the IHC analysis of ER may be a new powerful predictor of the BRCA1 mutation status. Estimations show that the probability of being a BRCA1-mutation carrier in a woman with FBC diagnosed before the age of 35 years with a grade 3 tumour and ER negative status is 25%. However, the probability falls to only 5% if the tumour is ER positive [1, 5].

The immunophenotypic features of breast carcinomas arising in BRCA1 mutation carriers have also been evaluated by Palacios et al, showing that only 25% of BRCA1-associated tumors were ER positive and PR negative, whereas all cases were HER2 negative [24].

It should be taken into account, however, that the use of IHC screening to select cases for BRCA1 mutational analysis may have some limitations. In fact, although the majority of BRCA1-mutant tumours lack ER expression, several studies have shown that a small number retain ER positivity [26, 27]. In addition, whereas the ER negative status is a highly sensitive predictor (ER-positive cases are rarely BRCA1 mutation carriers), this parameter has a limited specificity [1].

In this series of selected patients, a high prevalence of BRCA1 pathogenetic mutations was observed in FBCs with double or single negative receptorial status, showing that the evaluation of IHC characteristics can be useful not only for therapeutic purposes, but also for the identification of a subgroup of patients having a higher probability of being carriers of BRCA1 deleterious mutations. Furthermore, the evaluation of HER2 expression may also allow for a reduction of the number of patients who should undergo BRCA1 mutation screening.

Conclusion

The IHC analysis by Allred's method, a rapid and easily performed test, can be used before performing expensive mutation screening in order to select the high-risk cases who are most likely to carry a deleterious BRCA1 mutation. In patients selected by family history, the analysis of the cancer IHC phenotype allows the prediction of the BRCA1 genotype with a very high sensitivity and specificity.

About 90% of BRCA1 related cancers are ER negative and/or PR negative with weak HER2 expression [4, 5, 1921]. Although the IHC evaluation successfully allowed the limitation of the number of patients to be molecularly tested, a small proportion of cases carrying the BRCA1 mutations retained the ER expression.

Interestingly, our data confirm that the incidence of BRCA1 mutations in the ER and/or PR positive cancers is low. On these grounds, our combined selection approach could significantly reduce the number of patients who should undergo BRCA1 mutational analysis, with the possible limitation of missing one true BRCA1 mutation carrier every 100 patients selected by breast cancer familial history alone. Analysis of a larger series of cases is however required to validate the proposed selection approach.

Declarations

Acknowledgements

The authors thank the patients and their families for their cooperation.

The authors also thank Anna Maria Colussi for her assistance in editing the text.

The study was supported by funds from the Italian Ministry of Health, "Ricerca Corrente" programs and by Alleanza Contro il Cancro (funding given to AVi).

Authors’ Affiliations

(1)
Department of Molecular Oncology and Translational Research, Division of Experimental Oncology 1, Centro di Riferimento Oncologico, National Cancer Institute
(2)
Department of Senology, Division of Medical Oncology C, Centro di Riferimento Oncologico, National Cancer Institute
(3)
Department of Diagnostic Laboratories and Cell Therapy, Division of Pathology, Centro di Riferimento Oncologico, National Cancer Institute
(4)
Department of Medical Oncology, Cancer Biommunotherapy Unit, Centro di Riferimento Oncologico, National Cancer Institute

References

  1. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, Vijver van der M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF, Breast Cancer Linkage Consortium: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005, 11: 5175-5180. 10.1158/1078-0432.CCR-04-2424.View ArticlePubMedGoogle Scholar
  2. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA: Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004, 10: 2029-2034. 10.1158/1078-0432.CCR-03-1061.View ArticlePubMedGoogle Scholar
  3. Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K: BRCA-associated breast cancer in young women. J Clin Oncol. 1998, 16: 1642-1649.PubMedGoogle Scholar
  4. Chappuis PO, Nethercot V, Foulkes WD: Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol. 2000, 18: 287-295. 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5.View ArticlePubMedGoogle Scholar
  5. Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G: Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res. 2001, 7: 1937-1945.PubMedGoogle Scholar
  6. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998, 16: 2417-2425.PubMedGoogle Scholar
  7. Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998, 62: 145-158. 10.1086/301670.View ArticlePubMedPubMed CentralGoogle Scholar
  8. American Society of Clinical Oncology: American Society of Clinical Oncology Policy Statement update: Genetic Testing for Cancer Susceptibility. J Clin Oncol. 2003, 21: 2397-2406. 10.1200/JCO.2003.03.189.View ArticleGoogle Scholar
  9. Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Armstrong KA, Calzone K, Stopfer J, Seal S, Stratton MR, Weber BL: BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol. 2002, 20: 994-999. 10.1200/JCO.20.4.994.View ArticlePubMedGoogle Scholar
  10. Foretova L, Machackova E, Navratilova M, Pavlu H, Hruba M, Lukesova M, Valik D: BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum Mutat. 2004, 23: 397-398. 10.1002/humu.9226.View ArticlePubMedGoogle Scholar
  11. Capalbo C, Ricevuto E, Vestri A, Ristori E, Sidoni T, Buffone O, Adamo B, Cortesi E, Marchetti P, Scambia G, Tomao S, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G: BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. Ann Oncol. 2006, 17 (Suppl 7): vii34-vii40. 10.1093/annonc/mdl947.PubMedGoogle Scholar
  12. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949. 10.1093/jnci/91.11.943.View ArticlePubMedGoogle Scholar
  13. Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, Dolcetti R, Viel A, Crivellari D, Bidoli E, Boiocchi M: Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer. 2005, 5: 70-10.1186/1471-2407-5-70.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Wagner TM, Hirtenlehner K, Shen P, Moeslinger R, Muhr D, Fleischmann E, Concin H, Doeller W, Haid A, Lang AH, Mayer P, Petru E, Ropp E, Langbauer G, Kubista E, Scheiner O, Underhill P, Mountain J, Stierer M, Zielinski C, Oefner P: Global sequence diversity of BRCA2: analysis of 71 breast cancer families and 95 control individuals of worldwide populations. Hum Mol Genet. 1999, 8: 413-423. 10.1093/hmg/8.3.413. Erratum in Hum Mol Genet 8:717-719View ArticlePubMedGoogle Scholar
  15. Santarosa M, Viel A, Dolcetti R, Crivellari D, Magri MD, Pizzichetta MA, Tibiletti MG, Gallo A, Tumolo S, Del Tin L, Boiocchi M: Low incidence of BRCA1 mutations among Italian families with breast and ovarian cancer. Int J Cancer. 1998, 78: 581-586. 10.1002/(SICI)1097-0215(19981123)78:5<581::AID-IJC9>3.0.CO;2-G.View ArticlePubMedGoogle Scholar
  16. Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, Furlan D, Boiocchi M, Viel A: BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy. Int J Cancer. 1999, 83: 5-9. 10.1002/(SICI)1097-0215(19990924)83:1<5::AID-IJC2>3.0.CO;2-U.View ArticlePubMedGoogle Scholar
  17. The BIC (Breast Cancer Information Core) database. [http://www.nhgri.nih.gov/Intramural_research/Lab_transfer/Bic/]
  18. Allred DG, Harvey JM, Belardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMedGoogle Scholar
  19. Honrado B, Benitez J, Palacios J: The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol. 2005, 18: 1305-1320. 10.1038/modpathol.3800453.View ArticlePubMedGoogle Scholar
  20. Turner NC, Reis-Filho JS: Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006, 25: 5846-5853. 10.1038/sj.onc.1209876.View ArticlePubMedGoogle Scholar
  21. Tischkowitz MD, Foulkes WD: The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle. 2006, 5: 963-967.View ArticlePubMedGoogle Scholar
  22. Jóhannsson OT, Idvall I, Anderson C, Borg A, Barkardóttir RB, Egilsson V, Olsson H: Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer. 1997, 33: 362-371. 10.1016/S0959-8049(97)89007-7.View ArticlePubMedGoogle Scholar
  23. Osorio A, de la Hoya M, Rodriguez-Lopez R, Martínez-Ramírez A, Cazorla A, Granizo JJ, Esteller M, Rivas C, Caldés T, Benítez J: Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int J Cancer. 2002, 99: 305-309. 10.1002/ijc.10337.View ArticlePubMedGoogle Scholar
  24. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrió D, Barroso A, Rodríguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Sánchez L, Rivas C, Benítez J: Immunohistochemical characteristics defined by tissue Microarray of Hereditary Breast Cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res. 2003, 9: 3606-3614.PubMedGoogle Scholar
  25. Musolino A, Bella AM, Bortesi B, Michiara M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M, Neri TM, Ardizzoni A: BRCA mutations, molecular markers, and clinical variables in early-onset beast cancer: a population-based study. The Breast. 2007, 16: 280-292. 10.1016/j.breast.2006.12.003.View ArticlePubMedGoogle Scholar
  26. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD: Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer. 1997, 80: 435-441. 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y.View ArticlePubMedGoogle Scholar
  27. Verhoog LC, Brekelmans CT, Seynaeve C, Bosch van den LM, Dahmen G, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Wagner A, Ouweland van den A, Devilee P, Meijers-Heijboer EJ, Klijn JG: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998, 351: 316-321. 10.1016/S0140-6736(97)07065-7.View ArticlePubMedGoogle Scholar
  28. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/9/360/prepub

Copyright

© Miolo et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement